Wyeth reveals results of 5-year fracture study

Wyeth has announced the results of a five-year-long trial into the use of drug bazedoxifene in patients who have sustained vertebral fractures.

The phase III study showed a significant reduction in fractures was experienced by postmenopausal women with osteoporosis new vertebral fractures, when compared to a placebo treatment.

Bazedoxifene is a selective estrogen receptor modulator currently under clinical investigation for the prevention and treatment of postmenopausal osteoporosis and the trial involved the participation of 7,492 generally healthy postmenopausal women aged between 55 and 85

“These new data are important in that they suggest the reduction in vertebral fracture risk with bazedoxifene seen at five years is comparable to that seen at three years,” commented Stuart Silverman, the lead investigator of the study.

Last month, Wyeth revealed that it has recently submitted an extension application for its opioid-induced constipation therapy to the European Medicines Agency in order for the product to become available in pre-filled syringe form.